Siegfried, a global CDMO for the pharmaceutical industry, has signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience. The acquired businesses include three high-quality small molecules drug substances sites with approximately 400 employees:

Noramco, a large, commercial-scale manufacturing site in Wilmington, DE 

Purisys, a clinical API development and manufacturing facility in Athens, GA.

Extractas Bioscience, a manufacturer of purified products based in Westbury, Tasmania (AU)

The acquisition is part of Siegfried’s EVOLVE+ strategy to expand the company’s presence and capacity in the U.S., the world’s largest pharmaceutical market.

Siegfried plans to expand its growing exclusive synthesis business in the U.S. by optimizing its controlled substance capacity across the newly acquired Wilmington site and its nearby Pennsville site. Combined with the early-phase development capabilities of Purisys and the extraction expertise of Extractas Bioscience, the acquisition strengthens Siegfried’s integrated offering and provides a strong foundation for accelerating growth and improving profitability.

Marcel Imwinkelried, Chief Executive Officer: “This transaction marks a decisive next step in the execution of our EVOLVE+ strategy and is aligned with our highly selective, disciplined value accretive approach to M&A. By adding exceptional US-based capabilities, we will become even more attractive to both existing and new customers, creating new opportunities to accelerate profitable growth. The combined capacity and expertise of the three sites strengthen our position as a leading CDMO for small-molecule drug substances, and I look forward to fully realizing this value together with our new colleagues.”